Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857948 · ClinicalTrials.gov registry record · Phase 2
Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation
A Phase 2 study, sponsored by Topaz Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT00857948: Completed Phase 2 study, sponsored by Topaz Pharmaceuticals.
NCT00857948 is a Phase 2 study that has completed, run by Topaz Pharmaceuticals. The registered enrollment target is 78 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00857948, a Phase 2 study, has completed, sponsored by Topaz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.
Primary Outcome
Live lice eradication was assessed by visual checks of hair and scalp on Days 1, 2 and 8 and by visual checks and counting both live and dead lice from rinse water on Day 15. Eradication was defined as cessation of motility (antennae and leg movement) in all lice.
Interventions
- DRUG Placebo, vehicle control
- DRUG ivermectin treatment conditioner
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2009-03 |
| Est. Completion | 2009-04 |
| Phase | Phase 2 |
What the finished NCT00857948 record still lists
NCT00857948 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 78 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (41% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo, vehicle control is the first listed.
NCT00857948 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00857948 about?
NCT00857948 is a clinical study titled "Dose Ranging Study of Ivermectin Treatment Conditioner in Subjects With Head Lice Infestation". This is a Phase 2 single center study designed to compare the safety, local tolerability, and efficacy of 3 strengths of ivermectin treatment conditioner to placebo.
What is the current status of trial NCT00857948?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2009-03. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00857948?
The interventions under investigation include: Placebo, vehicle control (DRUG), ivermectin treatment conditioner (DRUG).
Who is sponsoring clinical trial NCT00857948?
This trial is sponsored by Topaz Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00857948's enrollment target sits among peer trials
78 884th of 2000 higher than 1,110 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02397668 · 78 participants · NA
CorMatrix Cor TRICUSPID ECM Valve Replacement Study
- NCT03321656 · 78 participants · Phase 2
Impact of Envarsus XR® on Kidney Biopsy Subclinical Rejection and Blood Immunologic Profile
- NCT03687814 · 78 participants · NA
Low FODMAP Plus PEG 3350 for the Treatment of Patients with Irritable Bowel Syndrome-Constipation
- NCT04018872 · 78 participants · Phase 2
Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia